All-in-one Hangzhou Protocol:killing four birds with one stone  

作　　者：Haopeng Wang Shizhen Qiu Mohamad Mohty 

机构地区：[1]School of Life Science and Technology,Shanghai Tech University,Shanghai,China [2]State Key Laboratory of Advanced Medical Materials and Devices,ShanghaiTech University,Shanghai,China [3]Shanghai Clinical Research and Trial Center,Shanghai,China [4]Department of Hematology,Shanghai General Hospital,Shanghai Jiaotong University School of Medicine,Shanghai,China [5]Department of Clinical Hematology and Cellular Therapy,Saint-Antoine Hospital,AP-HP,Sorbonne University,and INSERM,Saint-Antoine Research Centre,Paris,France

出　　处：《Cell Research》2024年第10期679-680,共2页细胞研究（英文版）

摘　　要：In a recent study published in The New England Journal of Medicine,researchers developed an innovative"all-in-one"treatment protocol that combines CD7^(+) chimeric antigen receptor T-cell therapy with subsequent haploidentical hematopoietic stem cell transplantation.This approach significantly advances the treatment of CD7^(+)hematological malignancies by eliminating the need for myeloablative chemotherapy and immunosuppressants for graft-versushostdiseaseprophylaxis.Chimeric antigen receptor(CAR)T-cell therapy utilizes synthetic antigen receptors targeting T lymphocytes to attack tumor cells specifically.

关 键 词：CHEMOTHERAPY utilize eliminating 

分 类 号：G236[文化科学]